Skip to main content

Health economic modeling for medical technologies in Europe

Early and comprehensive economic models to determine economic value proposition and inform healthcare decision-makers

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MedTech-related health technology assessments from NIHR in July 2023

The National Institute for Health and Care Research (NIHR) funds valuable independent research for health and social care decision-makers in England. Reports from the Health Technology Assessment (HTA) Programme are published in the NIHR HTA Journal and inform NICE guidance. 

In July 2023, NIHR released a systematic review concerning magnetic resonance imaging (MRI)-based technologies. The aim of the study was to assess the diagnostic test accuracy, clinical impact, and cost-effectiveness of two MRI-based technologies (LiverMultiScan and magnetic resonance elastography) for patients with non-alcoholic fatty liver disease (NAFLD).

It was concluded that MRI-based technologies may be useful in identifying patients who may benefit from additional testing in the form of liver biopsy and those for whom this additional testing may not be necessary. However, there is a paucity of diagnostic test accuracy and clinical impact data for patients who have indeterminate results from fibrosis testing, for whom transient elastography or acoustic radiation force impulse is unsuitable, or who had discordant results from fibrosis testing. The use of LiverMultiScan and magnetic resonance elastography for assessing NAFLD for patients with inconclusive results from previous fibrosis testing is unlikely to be a cost-effective use of NHS resources compared with liver biopsy only.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.